Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma
暂无分享,去创建一个
[1] T. Skaar,et al. Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition1 , 2009, The Journal of Immunology.
[2] Michelle Collazo,et al. Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.
[3] W. Nacken,et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.
[4] T. Skaar,et al. MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma1 , 2008, The Journal of Immunology.
[5] V. Bronte,et al. Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.
[6] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[7] P. De Baetselier,et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.
[8] D. Tuveson,et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.
[9] M. Smyth,et al. Immune surveillance of tumors. , 2007, The Journal of clinical investigation.
[10] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[11] Paolo Serafini,et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.
[12] Paolo Serafini,et al. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.
[13] M. Manns,et al. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. , 2006, Cancer research.
[14] E. Furth,et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. , 2006, Cancer research.
[15] E. Jaffee,et al. Immunotherapy for pancreatic cancer — science driving clinical progress , 2005, Nature Reviews Cancer.
[16] P. Sinha,et al. Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.
[17] J. Biggs,et al. A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+ T Lymphocytes into Effector CTL1 , 2004, The Journal of Immunology.
[18] S. Ostrand-Rosenberg,et al. Animal models of tumor immunity, immunotherapy and cancer vaccines. , 2004, Current opinion in immunology.
[19] M. Colombo,et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.
[20] T. Greten,et al. Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis ☆ ☆☆ , 2002 .
[21] T. Greten,et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. , 2002, Gastroenterology.
[22] T. Mattfeldt,et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. , 2001, Genes & development.
[23] R. Schmid,et al. Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. , 1998, Gastroenterology.